In this context, the inhibition of the oncogenic activity by developing MUC4β-ErbB2 protein-protein interaction (PPI) modulators appears as a promising therapeutic alternative in pancreatic cancer. The gene discussed is ERBB2; the disease is pancreatic neoplasm.